Age (yr) |
73.0 (63–80) |
71.0 (58–84) |
73.0 (67–78) |
.540 |
Gender-Male, N (%) |
75 (60.5%) |
42 (68.9%) |
33 (52.4%) |
.091 |
Body mass index, kg/m2
|
22.9 (19.8–26.4) |
24.4 (20.1–26.9) |
21.9 (19.4–26.1) |
.180 |
Current smoker, N (%) |
9 (7.3%) |
6 (9.8%) |
3 (4.8%) |
.493 |
Hypertension, N (%) |
95 (76.6%) |
45 (73.8%) |
50 (79.4%) |
.601 |
Diabetes mellitus, N (%) |
87 (70.2%) |
40 (65.6%) |
47 (74.6%) |
.367 |
Hyperlipidemia, N (%) |
32 (25.8%) |
11 (18%) |
21 (33.3%) |
.082 |
Chronic lung disease, N (%) |
13 (10.5%) |
9 (14.8%) |
4 (6.3%) |
.217 |
Congestive heart failure, N (%) |
44 (35.5%) |
20 (32.8%) |
24 (38.1%) |
.667 |
Coronary artery disease, N (%) |
44 (35.5%) |
19 (31.1%) |
25 (39.7%) |
.421 |
Old myocardial infarction, N (%) |
1 (0.8%) |
0 (0.0%) |
1 (1.6%) |
1.000 |
History of CABG, N (%) |
6 (4.8%) |
2 (3.3%) |
4 (6.3%) |
.680 |
Previous PCI, N (%) |
31 (25%) |
14 (23%) |
17 (27.0%) |
.756 |
History of peripheral artery disease, N (%) |
40 (32.3%) |
16 (26.2%) |
24 (38.1%) |
.222 |
Previous lower limb bypass, N (%) |
5 (4.0%) |
2 (3.3%) |
3 (4.8%) |
1.000 |
Prior stroke or TIA, N (%) |
17 (13.7%) |
6 (9.9%) |
11 (17.5%) |
.331 |
Current dialysis, N (%) |
43 (34.7%) |
17 (27.9%) |
26 (41.3%) |
.168 |
Chronic kidney disease∗, N (%) |
69 (55.6%) |
28 (45.9%) |
41 (65.1%) |
.049 |
Atrial fibrillation, N (%) |
18 (14.5%) |
6 (9.8%) |
12 (19.0%) |
.230 |
Collagen vascular disease, N (%) |
10 (8.1%) |
4 (6.6%) |
6 (9.5%) |
.744 |
Creatinine (mg/dL) |
1.4 (0.9–5) |
1.2 (0.8–4.5) |
1.8 (1–5.3) |
.229 |
Estimated GFR (ml/min) |
44.0 (10.4–84) |
63.1 (10.2–88.9) |
35.6 (10.5–74.9) |
.185 |
HbA1C (mg/dL) |
6.9 (6.1–8.7) |
7.0 (6.2–9.2) |
6.9 (6–8.4) |
.333 |
LDL cholesterol, mg/dL |
75.5 (56–101.8) |
77.0 (59–105) |
74.0 (54–101) |
.612 |
Hemoglobin, g/dL |
10.1 (8.6–11.7) |
10.8 (8.9–12.9) |
9.7 (8.5–10.7) |
.004 |
ABI |
0.8 (0.6–1) |
0.8 (0.6–1) |
0.8 (0.6–1) |
.664 |
Rutherford classification, N (%) |
|
|
|
<.001 |
Category 5 |
54 (43.5%) |
37 (60.7%) |
17 (27%) |
|
Category 6 |
70 (56.5%) |
24 (39.3%) |
46 (73.0%) |
|
University of Texas classification, N (%) |
|
|
|
.057 |
Grade 0 |
11 (8.9%) |
8 (13.1%) |
3 (4.8%) |
|
Grade 1 |
43 (34.7%) |
25 (41%) |
18 (28.6%) |
|
Grade 2 |
29 (23.4%) |
14 (23%) |
15 (23.8%) |
|
Grade 3 |
41 (33.1%) |
14 (23%) |
27 (42.9%) |
|
Infection, N (%) |
66 (53.2%) |
30 (49.2%) |
36 (57.1%) |
.479 |
Medications,N (%) |
Aspirin |
102 (82.3%) |
52 (85.2%) |
50 (79.4%) |
.534 |
Clopidogrel |
110 (88.7%) |
52 (85.2%) |
58 (92.1%) |
.360 |
Cilostazol |
80 (64.5%) |
43 (70.5%) |
37 (58.7%) |
.238 |
Pentoxifylline |
7 (5.6%) |
4 (6.6%) |
3 (4.8%) |
.715 |
Warfarin or NOAC |
11 (8.9%) |
5 (8.2%) |
6 (9.5%) |
1.000 |
ACEI/ARB |
54 (43.5%) |
24 (39.3%) |
30 (47.6%) |
.454 |
Statin |
74 (59.7%) |
36 (59.0%) |
38 (60.3%) |
1.000 |
Beta blocker |
38 (30.6%) |
14 (23%) |
24 (38.1%) |
.102 |
Calcium channel blocker |
61 (49.2%) |
32 (52.5%) |
29 (46.0%) |
.592 |
Insulin |
32 (25.8%) |
16 (26.2%) |
16 (25.4%) |
1.000 |
Prostaglandin E1 |
35 (28.2%) |
19 (31.1%) |
16 (25.4%) |
.609 |